Orbital Therapeutics
Cambridge, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $270M
Overview
Developer of a next-generation synthetic biology platform for engineered RNA therapeutics and vaccines.
Infectious DiseaseOncologyGenetic Disorders
Technology Platform
A synthetic biology platform for designing novel RNA constructs, advanced delivery systems, and scalable manufacturing processes to create next-generation RNA medicines.
Funding History
1Total raised:$270M
Series A$270M
Opportunities
Potential to define the next wave of RNA medicine with longer-lasting, targetable, and more complex therapeutic applications.
Risk Factors
Extreme technical and execution risk in developing novel RNA and delivery technologies that must outperform proven, commercially validated approaches.
Competitive Landscape
Competes in the highly advanced and crowded RNA therapeutics field, requiring breakthrough innovations in delivery or durability to displace established players.